KD2407

KD2407 is a generic drug candidate being developed by Kyungdong Pharmaceutical for the treatment of hypertension. It is currently in Phase 1 clinical development, specifically undergoing bioequivalence studies to demonstrate therapeutic equivalence to an existing reference listed antihypertensive drug. As a generic formulation, KD2407 is designed to provide a cost-effective alternative for blood pressure management. While the specific active pharmaceutical ingredient has not been publicly disclosed in the primary pipeline documentation, the project is part of Kyungdong Pharmaceutical's broader strategy to expand its cardiovascular portfolio through the development of high-quality generic medications.